Muscle & Performance

Best Peptides for Muscle & Performance

📄 13 PubMed citations

A tiered, evidence-first map of the compounds people stack for hypertrophy, strength, and recovery — sorted by how strong the human data actually is, and flagged for anti-doping status.

🔬 Most "best peptides for muscle" lists rank by hype. We rank by evidence tier and honesty: recovery peptides with the most human safety data first, growth-hormone-axis secretagogues second, and directly anabolic SARMs — the highest-risk, most-banned tier — last, with every compound's WADA category stated plainly.
3
Evidence tiers — recovery, GH-axis, anabolic
1.21kg
Lean mass in LGD-4033 3-week Phase 1 trial
100%
Of these compounds are WADA-prohibited in sport

How It Works

🩹
Tier 1 — Recovery peptides

BPC-157 and TB-500 (thymosin β4). The most human safety data of this group and the lowest-risk profile. They do not build muscle directly — they support tendon, ligament, and soft-tissue repair so you can train harder and recover faster. Best evidence-to-risk ratio here.

📈
Tier 2 — Growth-hormone axis

CJC-1295, ipamorelin, tesamorelin, sermorelin, MK-677. These raise your own GH and IGF-1 pulses rather than injecting HGH. Body-composition effects are real but modest; water retention, insulin resistance, and appetite (MK-677) are the trade-offs.

Tier 3 — Anabolic (SARMs)

LGD-4033, RAD-140, ostarine, and the follistatin/myostatin pathway. The only tier that adds lean mass directly and measurably — and the highest-risk: androgen suppression, liver-enzyme elevation, and lipid changes are documented. Non-approved for human use.

🚫
Anti-doping reality

Every compound on this page is banned in tested sport. SARMs sit in WADA class S1 (anabolic agents); GH secretagogues, GHRH analogs, and thymosin β4 in S2; BPC-157 is non-approved (S0). Detection windows run weeks to months.

What the Data Shows

BPC-157
Tendon / soft-tissue recovery
Human safety pilot + animal efficacy
TB-500 (Tβ4)
Wound & tissue repair
Preclinical + early human
CJC-1295 / Ipamorelin
GH / IGF-1 pulse
Human PK/PD trials
Tesamorelin
GHRH analog
FDA-approved (HIV lipodystrophy)
LGD-4033
Lean-mass SARM
Phase 1 human (3 weeks)
RAD-140
Most potent SARM
Preclinical + oncology Phase 1

WADA & Anti-Doping Status

If you are a drug-tested athlete, treat this entire page as off-limits. Every compound below is banned in competition under the World Anti-Doping Agency (WADA) Prohibited List, and modern assays detect SARMs and peptide hormones for weeks to months after the last dose. The categories below are how each class is listed on the WADA Prohibited List.

Compound class
WADA category
Status
SARMs — LGD-4033, RAD-140, Ostarine, S-23
Class S1.2
Prohibited at all times
GH secretagogues — CJC-1295, Ipamorelin, MK-677, GHRP-2/6
Class S2
Prohibited at all times
GHRH analog — Tesamorelin, Sermorelin
Class S2
Prohibited at all times
Thymosin β4 — TB-500
Class S2
Prohibited at all times
Follistatin / myostatin inhibitors
Class S4.5
Prohibited at all times
BPC-157
Class S0
Non-approved → prohibited

Categories reflect the WADA Prohibited List classification for each substance group; always check the current year's list before competing. For a compound-specific breakdown, see our BPC-157 WADA status page.

Key Takeaways

✅ What We Know
  • Recovery peptides (BPC-157, TB-500) have the most human safety data of this group and the lowest-risk profile — but they support repair, they do not add muscle directly.
  • CJC-1295 + ipamorelin raise endogenous GH and IGF-1 in controlled human trials; tesamorelin is FDA-approved (for HIV-associated visceral fat), proving the GHRH mechanism works in humans.
  • LGD-4033 produced dose-dependent lean-mass gains in a 3-week Phase 1 study in healthy young men — the clearest direct-anabolic signal in this tier.
  • Loss of myostatin drives large muscle hypertrophy — documented in a child with a myostatin mutation and in follistatin gene-therapy primate studies — the biological rationale for the anabolic tier.
  • Every compound here is prohibited in tested sport; SARMs and GH secretagogues carry documented suppression, liver, and lipid risks.
⚠️ What We Don't Know
  • No head-to-head human trial ranks these compounds against each other for hypertrophy — the tiering is by evidence quality and risk, not a proven potency order.
  • Long-term safety of BPC-157 and TB-500 in humans is essentially unstudied beyond small pilots.
  • Optimal dosing, cycle length, and stacking for muscle outcomes are not established by controlled trials — most protocols are anecdotal.
  • SARM liver injury and androgen suppression are documented, but their frequency and reversibility across doses are not well quantified.
  • None of these are FDA-approved for muscle building; the purity and dosing of research-grade product are unverified.

Frequently Asked Questions

What is the best peptide for muscle growth?

No single peptide "builds muscle" the way an anabolic steroid does. The strongest direct lean-mass signal comes from SARMs like LGD-4033 (a 3-week Phase 1 trial showed dose-dependent lean mass), but these are non-approved and WADA-prohibited. Recovery peptides (BPC-157, TB-500) and GH-axis secretagogues (CJC-1295/ipamorelin) support training and recovery rather than adding muscle directly.

Are muscle-building peptides and SARMs legal?

None of the compounds on this page are FDA-approved for muscle building. SARMs are not approved for human use and are sold only as research chemicals. In tested sport, all of them are prohibited by WADA — SARMs under class S1, GH secretagogues and thymosin β4 under S2, and BPC-157 as a non-approved substance.

Do peptides like BPC-157 build muscle?

BPC-157 is a recovery peptide, not an anabolic. Its studied effects are on tendon, ligament, gut, and soft-tissue healing — it may let you train harder and recover faster, but there is no human trial showing it increases muscle mass on its own.

Which is safest — recovery peptides, GH secretagogues, or SARMs?

By available human evidence, recovery peptides carry the lowest risk, GH-axis secretagogues are intermediate (water retention, insulin resistance, and appetite with MK-677), and SARMs are the highest-risk tier with documented androgen suppression, liver-enzyme elevation, and lipid changes.

🔬 Research-Grade Source

Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.

Browse Swiss Chems →
Code HIGHPEP10 — 10% off regular-priced items

Affiliate link — supports HighPeptides at no extra cost

Peer-Reviewed References

Source 1
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Alternative Therapies in Health and Medicine · 2021
PMID: 34324435
Source 2
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Alternative Therapies in Health and Medicine · 2025
PMID: 40131143
Source 3
Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.
Journal of Orthopaedic Surgery and Research · 2019
PMID: 31266512
Source 4
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.
Wound Repair and Regeneration · 2003
PMID: 12581423
Source 5
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.
Nature · 2004
PMID: 15565145
Source 6
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Journal of Clinical Endocrinology and Metabolism · 2006
PMID: 16352683
Source 7
Ipamorelin, the first selective growth hormone secretagogue.
European Journal of Endocrinology · 1998
PMID: 9849822
Source 8
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
JAMA · 2014
PMID: 25038357
Source 9
Growth hormone-releasing hormone and corticotropin-releasing hormone enhance non-rapid-eye-movement sleep after sleep deprivation.
American Journal of Physiology - Endocrinology and Metabolism · 2006
PMID: 16912060
Source 10
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
The Journals of Gerontology, Series A · 2013
PMID: 22459616
Source 11
Ligandrol (LGD-4033)-Induced Liver Injury.
ACG Case Reports Journal · 2020
PMID: 32637435
Source 12
Myostatin mutation associated with gross muscle hypertrophy in a child.
The New England Journal of Medicine · 2004
PMID: 15215484
Source 13
Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.
Science Translational Medicine · 2009
PMID: 20368179
⚠️ Disclaimer

Educational purposes only. Not medical advice.

None of the compounds discussed are approved by the FDA for muscle growth or athletic performance. SARMs and research peptides are sold for laboratory research use only.

All compounds on this page are prohibited in tested competition by WADA. If you are a drug-tested athlete, do not use them.

Always consult a qualified healthcare provider before using any research compound.